EyeWorld Weekly, November 3, 2023
➤ FDA expands eye drop warning list ➤ Positive results in Phase 2a trial for new biodegradable sustained drug delivery implant ➤ Phase 2b study begins for investigational therapy for acute infectious conjunctivitis ➤ FDA approves additional treatment indication for bispecific antibody ➤ Enrollment complete for study evaluating femtosecond laser-created trabeculotomy ➤ Company to study personalized medicine for patients with wet AMD ➤ Enrollment complete for Phase 2b trial evaluating wet AMD therapy ➤ Pivotal trial for wet AMD therapy begins ➤ Survey evaluates female ophthalmologist experiences ➤ ASCRS news and events
Comments Off on EyeWorld Weekly, November 3, 2023
November 3, 2023
